Company intelligence

CRIS

Curis, Inc. · NASDAQ · Healthcare

Price$1.60+0.63% · +$0.01

Market cap3.12MEquity value

P / E-1.0Trailing ratio

Volume56.95KLatest session

Market data

CRIS price chart

TradingView

Related signals

1 min delayed

Browse public CRIS signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CRISJul 24, 2026-2.79% since signal

Analyst raises CRIS PT to $43 on TakeAim CLL and timeline shifts

HC Wainwright raises CRIS's price target to $43 on TakeAim CLL progress and potential CLL, PCNSL, and NHL opportunities. Key timelines shift with PCNSL to 2029 and AML/MDS to 2032; enrollment targeted by 2027 and potential accelerated approvals, supported by improving DoR in BTKi-experienced patients. The readouts could be near-term catalysts for upside if data meet expectations.

View signal analysis

CRISJul 22, 2026+4.00% since signal

Curis updates boost PCNSL data and CLL enrollment, signaling regulatory optionality

Curis announced updated TakeAim PCNSL results and stronger TakeAim CLL enrollment, with year-end data guidance raised. BTKi-naïve PCNSL patients show 100% ORR; BTKi-experienced 33% ORR, signaling potential regulatory progress. While data quality supports a near-term regulatory pathway, the company’s cash runway remains a funding risk.

View signal analysis

Research